Ascoril expectorant, syrup, 100ml

Composition

10 ml of syrup contains:

Active ingredients:  

• salbutamol (in the form of sulfate) 2 mg,

• Bromhexinee hydrochloride 4 mg,

• guaifenesin 100 mg,

• menthol 1 mg;

Auxiliary substances:  

• flavorings,

• sucrose,

• sodium benzoate,

• sorbitol,

• glycerol,

• propylene glycol,

• sunset yellow dye,

• purified water.

Pharmacological action

Ascoril expectorant – bronchodilator, mucolytic, expectorant.

Pharmacodynamics

Combined drug, has a bronchodilator, expectorant and mucolytic effect.

Salbutamol is a bronchodilator that stimulates the beta_-2adrenergic receptors of the bronchi, blood vessels and myometrium. Prevents or eliminates bronchial spasm, reduces resistance in the airways, increases the vital capacity of the lungs. Causes dilation of the coronary arteries, does not reduce blood pressure.

Bromhexinee is a mucolytic agent that has an expectorant and antitussive effect. Increases the serous component of bronchial secretions; activates cilia of the ciliated epithelium, reduces the viscosity of sputum, increases its volume and improves discharge.

Guaifenesin is a mucolytic agent that reduces the surface tension of the structures of the bronchopulmonary apparatus; it stimulates secretory cells of the bronchial mucosa that produce neutral polysaccharides, depolymerizes acidic mucopolysaccharides, reduces the viscosity of sputum, activates the ciliary apparatus of the bronchi, facilitates sputum removal and promotes the transition of an unproductive cough to a productive one.

Pharmacokinetics

Salbutamol

When taken orally, the absorption is high. Food intake reduces the rate of absorption, but does not affect bioavailability. Binding to plasma proteins is 10%. Penetrates through the placenta. It undergoes presystemic metabolism in the liver and intestinal wall, and is inactivated by phenolsulfotransferase to 4-o-sulfate ether. T_1/2 — 3,8–6 h. It is excreted by the kidneys (69-90%), mainly as an inactive phenol sulfate metabolite (60%) within 72 hours and with bile (4%). The bioavailability of orally administered salbutamol is about 50%.

Bromhexinee

When taken orally, it is almost completely (99%) absorbed into the gastrointestinal tract within 30 minutes. Bioavailability is low (the effect of primary passage through the liver). Penetrates the placental barrier and BBB. In the liver, it undergoes demethylation and oxidation, and is metabolized to the pharmacologically active ambroxol. T_1/2-15 h (due to slow back diffusion from the tissues). It is excreted by the kidneys. In CRF, the elimination of metabolites is disrupted. With repeated use, it can accumulate.

Guaifenesin

Absorption from the gastrointestinal tract is rapid (25-30 minutes after ingestion). T_1/2-1 h. Penetrates into tissues containing acidic mucopolysaccharides. Approximately 60% of the administered drug is metabolized in the liver. It is excreted by the lungs (with sputum) and kidneys both in unchanged form and in the form of inactive metabolites.

Indications

As part of the combined therapy of acute and chronic bronchopulmonary diseases, accompanied by the formation of difficult-to-separate viscous secretions:

• bronchial asthma;
• pneumoconiosis;
• obstructive bronchitis;
• tracheobronchitis;
• pneumonia;
• emphysema of the lungs;
• whooping cough;
• pulmonary tuberculosis.

Use during pregnancy and lactation

Contraindicated in pregnancy and children under three years of age

Contraindications

• tachyarrhythmia;
• myocarditis;
• heart defects;
• decompensated diabetes mellitus;
• thyrotoxicosis;
• glaucoma;
• liver or kidney failure;
• peptic ulcer of the stomach and duodenum in the acute stage;
• pregnancy;
• lactation;
• hypersensitivity to the components of the drug.

With caution, it is prescribed to patients with diabetes mellitus, arterial hypertension, peptic ulcer of the stomach and duodenum in remission.

Side effects

Rarely when used in high doses:  

• headache,
• dizziness,
• increased nervous excitability,
• sleep disturbance,
• drowsiness,
• tremor,
• convulsions,
• nausea,
• vomiting,
• diarrhea,
• exacerbation of gastric and duodenal ulcers,
• rapid heartbeat,
• possible staining of urine in pink,
• allergic reactions (rash, urticaria),
• collapse,
• bronchospasm.

Interaction

Other beta-2-adrenomimetic agents and theophylline enhance the effect of salbutamol and increase the likelihood of side effects.

Ascoril is not prescribed simultaneously with drugs containing codeine, and other antitussive agents, because this makes it difficult to remove diluted sputum.

Ascoryl Bromhexinee, which is part of the drug, promotes the penetration of antibiotics (erythromycin, cephalexin, oxytetracycline) into the lung tissue.

It is not recommended to use Ascoril concomitantly with non-selective beta – blockers, such as propranolol.

Ascoril salbutamol is not recommended for patients receiving MAO inhibitors.

Diuretics and corticosteroids enhance the hypokalemic effect of salbutamol.

It is not recommended to take at the same time with the drug Ascoril alkaline drink.

How to take, course of use and dosage

Inside.

 Adults and children over 12 years of age — 10 ml (2 teaspoons) 3 times a day.

Children under 6 years of age — 5 ml (1 hour). spoon) 3 times a day,6-12 years-5-10 ml (1-2 hours).2 tablespoons) 3 times a day.

Overdose

Symptoms:  increased manifestations of side effects.

Treatment:  symptomatic therapy.

Form of production

Syrup

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

2 years

Active ingredient

Bromhexinee, Guaifenesine, Salbutamol

Conditions of release from pharmacies

By prescription

Dosage form

solution for oral use

Description

Children as prescribed by a doctor, Adults as prescribed by a doctor

Indications

Bronchitis, Chronic obstructive pulmonary disease, Whooping cough, Pneumonia, Bronchial asthma, Tuberculosis